<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPM-B Review the category designation for pemetrexed in the second-line setting.</td>
<td>Based on the data in the noted reference, the panel consensus was to change the category designation for pemetrexed in the second-line setting from a category 2A to a category 1. Based on the data in the noted reference, the panel consensus was to add the following consideration in the second-line setting: “Consider rechallenge if good sustained response at the time initial chemotherapy was interrupted.”</td>
<td>Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704. Zucal PA, Simonelli M, Michetti G, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012;75:360-367.</td>
<td>20 0 0</td>
</tr>
<tr>
<td>Consider recommending pemetrexed for peritoneal mesothelioma and tunica vaginalis testis mesothelioma.</td>
<td>Based on the data in the noted reference, the panel consensus was to add the following footnote: “Pemetrexed-based chemotherapy may also be used for peritoneal mesothelioma and tunica vaginalis testis mesothelioma.”</td>
<td>Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agents. Lung Cancer 2009;64:211-218.</td>
<td>20 0 0</td>
</tr>
</tbody>
</table>